Dashboard
Manage Tickers

GERN GERON CORP

Nasdaq geron.com


$ 1.30 $ 0.04 (3.23 %)    

Wednesday, 15-Oct-2025 19:00:47 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 602.61 $ 4.22 (0.71 %)
DIA $ 463.04 $ 0.00 (0 %)
SPY $ 665.11 $ 2.94 (0.44 %)
TLT $ 90.76 $ -0.20 (-0.22 %)
GLD $ 387.41 $ 6.60 (1.73 %)
$ 1.28
$ 1.27
$ 1.27 x 152
$ 1.30 x 1,998
$ 1.25 - $ 1.31
$ 1.09 - $ 4.50
10,999,146
na
816.66M
$ 0.88
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-06-2025 06-30-2025 10-Q
2 05-07-2025 03-31-2025 10-Q
3 02-26-2025 12-31-2024 10-K
4 11-07-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-02-2024 03-31-2024 10-Q
7 02-28-2024 12-31-2023 10-K
8 11-02-2023 09-30-2023 10-Q
9 08-03-2023 06-30-2023 10-Q
10 05-11-2023 03-31-2023 10-Q
11 03-16-2023 12-31-2022 10-K
12 11-07-2022 09-30-2022 10-Q
13 08-11-2022 06-30-2022 10-Q
14 05-09-2022 03-31-2022 10-Q
15 03-10-2022 12-31-2021 10-K
16 11-09-2021 09-30-2021 10-Q
17 08-16-2021 06-30-2021 10-Q
18 05-10-2021 03-31-2021 10-Q
19 03-11-2021 12-31-2020 10-K
20 11-05-2020 09-30-2020 10-Q
21 08-06-2020 06-30-2020 10-Q
22 05-28-2020 03-31-2020 10-Q
23 03-12-2020 12-31-2019 10-K
24 11-06-2019 09-30-2019 10-Q
25 08-01-2019 06-30-2019 10-Q
26 05-02-2019 03-31-2019 10-Q
27 03-07-2019 12-31-2018 10-K
28 11-01-2018 09-30-2018 10-Q
29 07-31-2018 06-30-2018 10-Q
30 05-10-2018 03-31-2018 10-Q
31 03-16-2018 12-31-2017 10-K
32 11-01-2017 09-30-2017 10-Q
33 08-09-2017 06-30-2017 10-Q
34 05-09-2017 03-31-2017 10-Q
35 03-01-2017 12-31-2016 10-K
36 11-03-2016 09-30-2016 10-Q
37 08-03-2016 06-30-2016 10-Q
38 05-05-2016 03-31-2016 10-Q
39 03-10-2016 12-31-2015 10-K
40 11-05-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

gerons-coo-andrew-grethlein-to-depart-on-october-15-2025
Geron's COO Andrew Grethlein To Depart On ...
10/13/2025 20:42:13

FOSTER CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical co...

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
08/06/2025 12:08:40

geron-appoints-harout-semerjian-as-president-and-ceo-effective-tomorrow-succeeding-dawn-carter-bir-to-accelerate-rytelo-commercialization-and-phase-3-impactmf-trial
Geron Appoints Harout Semerjian As Preside...
08/06/2025 11:31:34

geron-q2-eps-002-beats-003-estimate-sales-49036m-beat-47281m-estimate
Geron Q2 EPS $(0.02) Beats $(0.03) Estimat...
08/06/2025 11:03:36

Geron (NASDAQ:GERN) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.03) by 33.3...

Core News & Articles
Earnings Scheduled For August 6, 2025
08/06/2025 08:33:21

goldman-sachs-reinstates-sell-on-geron-announces-1-price-target
Goldman Sachs Reinstates Sell on Geron, An...
07/10/2025 13:04:42

Goldman Sachs analyst Corinne Jenkins reinstates Geron (NASDAQ:GERN) with a Sell and announces $1 price target.

goldman-sachs-initiates-coverage-on-geron-with-sell-rating-announces-price-target-of-1
Goldman Sachs Initiates Coverage On Geron ...
07/10/2025 12:52:39

Goldman Sachs analyst Corinne Jenkins initiates coverage on Geron (NASDAQ:GERN) with a Sell rating and announces Price Targe...

geron-highlights-new-imerge-post-hoc-analyses-demonstrating-rytelos-clinical-benefit-in-lower-risk-mds-patients-across-key-subgroups-alongside-quality-of-life-and-transfusion-independence-data-at-asco-and-eha-2025
Geron Highlights New IMerge Post-Hoc Analy...
05/28/2025 12:40:50

New post-hoc analyses from the IMerge trial show clinical benefit with RYTELO across patients with lower-risk myelodysplastic s...

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
05/07/2025 12:09:25

geron-q1-eps-003-beats-004-estimate-sales-3960m-miss-4822m-estimate
Geron Q1 EPS $(0.03) Beats $(0.04) Estimat...
05/07/2025 11:01:01

Geron (NASDAQ:GERN) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.04) by 25 p...

Core News & Articles
Earnings Scheduled For May 7, 2025
05/07/2025 08:33:08

10-health-care-stocks-whale-activity-in-todays-session
10 Health Care Stocks Whale Activity In To...
03/21/2025 17:35:16

needham-reiterates-buy-on-geron-maintains-5-price-target
Needham Reiterates Buy on Geron, Maintains...
03/12/2025 11:24:06

Needham analyst Gil Blum reiterates Geron (NASDAQ:GERN) with a Buy and maintains $5 price target.

hc-wainwright--co-reiterates-neutral-on-geronto-neutral
HC Wainwright & Co. Reiterates Neutral on ...
03/12/2025 11:17:28

HC Wainwright & Co. analyst Emily Bodnar reiterates Geron (NASDAQ:GERN) from Neutral to Neutral.

geron-corporation-announces-that-the-european-commission-has-granted-marketing-authorization-for-rytelo-as-a-monotherapy-for-the-treatment-of-adult-patients-with-transfusion-dependent-anemia
Geron Corporation Announces That The Europ...
03/11/2025 20:33:57

geron-corporation-announces-that-john-chip-a-scarlett-md-president-chief-executive-officer-and-chairman-will-depart-the-company-effective-march-31-2025
Geron Corporation Announces That John "Chi...
03/11/2025 20:05:25

scotiabank-maintains-sector-outperform-on-geron-lowers-price-target-to-4
Scotiabank Maintains Sector Outperform on ...
02/27/2025 18:07:24

Scotiabank analyst Greg Harrison maintains Geron (NASDAQ:GERN) with a Sector Outperform and lowers the price target from $6 ...

stifel-maintains-buy-on-geron-lowers-price-target-to-4
Stifel Maintains Buy on Geron, Lowers Pric...
02/27/2025 15:28:36

Stifel analyst Stephen Willey maintains Geron (NASDAQ:GERN) with a Buy and lowers the price target from $8 to $4.

barclays-maintains-overweight-on-geron-lowers-price-target-to-4
Barclays Maintains Overweight on Geron, Lo...
02/27/2025 11:57:45

Barclays analyst Peter Lawson maintains Geron (NASDAQ:GERN) with a Overweight and lowers the price target from $9 to $4.

needham-maintains-buy-on-geron-lowers-price-target-to-5
Needham Maintains Buy on Geron, Lowers Pri...
02/27/2025 09:46:07

Needham analyst Gil Blum maintains Geron (NASDAQ:GERN) with a Buy and lowers the price target from $7 to $5.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION